University of Washington
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).
University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.
University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.
Top-decile sponsor footprint
University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,048 total, page 10 of 21
Intervention Trial to Reduce Mental Health Disparities in Latina Immigrant Women
NCT03545282
Nicotinamide Riboside in LVAD Recipients
NCT03727646
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
NCT03534284
Gent for Pharyngeal Gonorrhea (GC)
NCT03632109
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
NCT03570476
BPO vs Hibiclens Soap for Surgical Preparation
NCT04021524
Back on Track to Healthy Living Study
NCT03687762
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
NCT03516812
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
NCT03260504
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
NCT03442556
IT Enhanced Peer Integrated Collaborative Care for US Trauma Care Systems
NCT03569878
Continuous Glucose Monitoring During and After Surgery
NCT02572856
Classifying and Predicting Long-term Pain and Function in Older Adults
NCT04864223
tSCI Contrast Enhanced Ultrasound Study
NCT04056988
A Lay-Led Intervention for War and Refugee Related Trauma
NCT03502278
Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users
NCT03584282
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
NCT03498612
Subgroups of Older Adults With Back Pain and Multiple Chronic Conditions
NCT03632122
Project to Improve Communication About Serious Illness - Pilot Study
NCT03746392
Remote Training in Evidence-based Practices for Clinicians Who Work With Migrant Workers
NCT03515226
Motivating Campus Change Project Pilot Study
NCT03962751
TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)
NCT03523923
Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation
NCT03576716
Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex
NCT03543826
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03522584
Personalized Blood Flow Restriction for Anterior Cruciate Ligament Rehabilitation
NCT04635579
Interoceptive Engagement
NCT03583060
Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.
NCT03509675
Microprocessor Knees in Early Rehabilitation
NCT03433300
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
NCT03401853
Activating and Connecting Teens (ACT) Study
NCT03438656
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
NCT03174353
Brain Injury Rehabilitation Improving the Transition Experience
NCT03422276
Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest
NCT03452917
A Prospective Trial of Virtual Home Rehabilitation After Burn Injury
NCT03475654
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT03256045
Training Resiliency in Youth (TRY) Study
NCT03429465
Efficacy Trial of Stress Check-Up
NCT03423394
CESM ABMR Breast Cancer Screening Trial
NCT03517813
Families Together: Intervention for Reunified Families
NCT04382677
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
NCT03269552
Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury
NCT03184792
Dental Hygiene and Peri-Implant Tissues Homeostasis Ancillary Study
NCT03917264
Dental Hygiene and Peri-Implant Tissues Homeostasis
NCT03384446
Text Message Intervention to Improve Cardiac Rehab Participation
NCT03346278
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
NCT02721979
Preventing Addiction Related Suicide (PARS)
NCT03166709
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
NCT03125226
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
NCT03062267
The Flipped Classroom Approach in Ophthalmology Residency
NCT04381676
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 127 |
| Phase 2 | 193 |
| Phase 3 | 39 |
| Phase 4 | 65 |
What is open in the University of Washington pipeline
156 recruiting of 1,048 indexed (15% open); 720 completed (69%).
Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).
Top condition: Depression (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Washington: open-pipeline peers nationwide
Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,048 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Arizona State University · 15% recruiting · 187 trials
- Georgetown University · 15% recruiting · 227 trials
Related
What to do with this University of Washington page
1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.
- 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.